-
Je něco špatně v tomto záznamu ?
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications
B. Godman, A. Hill, S. Simoens, G. Selke, I. Selke Krulichová, C. Zampirolli Dias, AP. Martin, W. Oortwijn, A. Timoney, LL. Gustafsson, L. Voncina, HY. Kwon, J. Gulbinovic, D. Gotham, J. Wale, W. Cristina Da Silva, T. Bochenek, E. Allocati, A....
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články
- MeSH
- dávkové mechanismy ekonomika MeSH
- ekonomické modely MeSH
- lidé MeSH
- nádory farmakoterapie ekonomika MeSH
- náklady a analýza nákladů MeSH
- náklady na léky trendy MeSH
- patenty jako téma MeSH
- poskytování zdravotní péče ekonomika MeSH
- protinádorové látky ekonomika MeSH
- vyvíjení léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Evropa MeSH
Introduction: There are growing concerns among European health authorities regarding increasing prices for new cancer medicines, prices not necessarily linked to health gain and the implications for the sustainability of their healthcare systems.Areas covered: Narrative discussion principally among payers and their advisers regarding potential approaches to the pricing of new cancer medicines.Expert opinion: A number of potential pricing approaches are discussed including minimum effectiveness levels for new cancer medicines, managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing, fair pricing models, amortization models as well as de-linkage models. We are likely to see a growth in alternative pricing deliberations in view of ongoing challenges. These include the considerable number of new oncology medicines in development including new gene therapies, new oncology medicines being launched with uncertainty regarding their value, and continued high prices coupled with the extent of confidential discounts for reimbursement. However, balanced against the need for new cancer medicines. This will lead to greater scrutiny over the prices of patent oncology medicines as more standard medicines lose their patent, calls for greater transparency as well as new models including amortization models. We will be monitoring these developments.
College of Pharmacy Ewha Woman's University Seoul South Korea
Data and Knowledge Integration Center for Health Salvador Bahia Brazil
Department for Health Evidence Radboud University Medical Center Nijmegen The Netherlands
Department of Medicine Lagos State University Teaching Hospital Ikeja Lagos Nigeria
Department of Pharmaceutical Affairs Federation of Social Insurances Vienna Austria
Department of Pharmaceutical and Pharmacological Sciences KU Leuven Belgium
Department of Pharmacology College of Pharmacy Hawler Medical University Erbil Iraq
Department of Pharmacy Faculty of Medicine University of Medicine Tirana Albania
Department of Pharmacy Ministry of Health of the Republic of Lithuania Vilnius Lithuania
Division of Biology and Public Health Mokwon University Daejeon Korea
Drug Department Catalan Health Service Catalan Health Service Barcelona Spain
Faculty of Health and Life Sciences Liverpool UK
Faculty of Health Studies Rijeka Croatia
Faculty of Medicine Slovak Medical University in Bratislava Bratislava Slovakia
Faculty of Pharmacy UBT Higher Education Institution Prishtina Kosovo
Health Insurance Institute Ljubljana Slovenia
Independent Consumer Advocate Brunswick Victoria Australia
Independent Researcher Boston MA United States
Institute of Translational Medicine University of Liverpool UK
Istituto Di Ricerche Farmacologiche 'Mario Negri' IRCCS Milan Italy
National Health Care Institute XH Diemen Netherlands
Pharmaceutical Drug Department Azienda Sanitaria Locale of Verona Verona Italy
Public Health Scotland Edinburgh UK
QC Medica Sim Balk Lane York UK
Reviews and Health Technology Assessments Norwegian Institute of Public Health Oslo Norway
School of National and Kapodistrian University of Athens Athens Greece
School of Pharmaceutical Sciences Universiti Sains Malaysia Penang Malaysia
State Agency of Medicines Tartu Estonia
Statistics Department Bruxelles Belgium
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21025211
- 003
- CZ-PrNML
- 005
- 20211026134023.0
- 007
- ta
- 008
- 211013s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/14737167.2021.1884546 $2 doi
- 035 __
- $a (PubMed)33535841
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Godman, Brian $u Division of Clinical Pharmacology, Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm, Sweden $u Division of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK $u Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa $u School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia
- 245 10
- $a Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications / $c B. Godman, A. Hill, S. Simoens, G. Selke, I. Selke Krulichová, C. Zampirolli Dias, AP. Martin, W. Oortwijn, A. Timoney, LL. Gustafsson, L. Voncina, HY. Kwon, J. Gulbinovic, D. Gotham, J. Wale, W. Cristina Da Silva, T. Bochenek, E. Allocati, A. Kurdi, OO. Ogunleye, JC. Meyer, I. Hoxha, A. Malaj, C. Hierländer, R. Sauermann, W. Hamelinck, G. Petrova, O. Laius, I. Langner, J. Yfantopoulos, R. Joppi, A. Jakupi, I. Greiciute-Kuprijanov, P. Vella Bonanno, JH. Piepenbrink, V. de Valk, M. Wladysiuk, V. Marković-Peković, I. Mardare, J. Fürst, D. Tomek, M. Obach Cortadellas, C. Zara, C. Pontes, S. McTaggart, TL. Laba, Ø. Melien, D. Wong-Rieger, S. Bae, R. Hill
- 520 9_
- $a Introduction: There are growing concerns among European health authorities regarding increasing prices for new cancer medicines, prices not necessarily linked to health gain and the implications for the sustainability of their healthcare systems.Areas covered: Narrative discussion principally among payers and their advisers regarding potential approaches to the pricing of new cancer medicines.Expert opinion: A number of potential pricing approaches are discussed including minimum effectiveness levels for new cancer medicines, managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing, fair pricing models, amortization models as well as de-linkage models. We are likely to see a growth in alternative pricing deliberations in view of ongoing challenges. These include the considerable number of new oncology medicines in development including new gene therapies, new oncology medicines being launched with uncertainty regarding their value, and continued high prices coupled with the extent of confidential discounts for reimbursement. However, balanced against the need for new cancer medicines. This will lead to greater scrutiny over the prices of patent oncology medicines as more standard medicines lose their patent, calls for greater transparency as well as new models including amortization models. We will be monitoring these developments.
- 650 _2
- $a protinádorové látky $x ekonomika $7 D000970
- 650 _2
- $a náklady a analýza nákladů $7 D003365
- 650 _2
- $a poskytování zdravotní péče $x ekonomika $7 D003695
- 650 _2
- $a náklady na léky $x trendy $7 D016527
- 650 _2
- $a vyvíjení léků $7 D000076722
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ekonomické modely $7 D018803
- 650 _2
- $a nádory $x farmakoterapie $x ekonomika $7 D009369
- 650 _2
- $a patenty jako téma $7 D010330
- 650 _2
- $a dávkové mechanismy $x ekonomika $7 D012051
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hill, Andrew $u Institute of Translational Medicine, University of Liverpool, UK
- 700 1_
- $a Simoens, Steven $u Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium
- 700 1_
- $a Selke, Gisbert $u Wissenschaftliches Institut Der AOK (WIdO), Berlin, Germany
- 700 1_
- $a Selke Krulichová, Iva $u Department of Medical Biophysics, Faculty of Medicine in Hradec Králové, Charles University, Hradec, Králové, Czech Republic
- 700 1_
- $a Zampirolli Dias, Carolina $u Faculty of Pharmacy, Postgraduate Program in Medicines and Pharmaceutical Services, Federal University of Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil $u SUS Collaborating Centre for Technology Assessment and Excellence in Health (CCATES), Belo Horizonte, Minas Gerais, Brazil
- 700 1_
- $a Martin, Antony P $u Faculty of Health and Life Sciences, Liverpool, UK $u QC Medica, Sim Balk Lane, York UK
- 700 1_
- $a Oortwijn, Wija $u Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands
- 700 1_
- $a Timoney, Angela $u Division of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK $u NHS Lothian, Edinburgh, UK
- 700 1_
- $a Gustafsson, Lars L $u Division of Clinical Pharmacology, Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm, Sweden
- 700 1_
- $a Voncina, Luka $u Faculty of Health Studies, Rijeka, Croatia
- 700 1_
- $a Kwon, Hye-Young $u Division of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK $u Division of Biology & Public Health, Mokwon University, Daejeon, Korea
- 700 1_
- $a Gulbinovic, Jolanta $u Department of Pathology, Forensic Medicine and Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
- 700 1_
- $a Gotham, Dzintars $u Independent Researcher, Boston, MA, United States
- 700 1_
- $a Wale, Janet $u Independent Consumer Advocate, Brunswick, Victoria, Australia
- 700 1_
- $a Cristina Da Silva, Wânia $u Faculty of Pharmacy, Postgraduate Program in Medicines and Pharmaceutical Services, Federal University of Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil $u Data and Knowledge Integration Center for Health(CIDACS), Fundação Oswaldo Cruz (FIOCRUZ)/ Salvador, Bahia, Brazil
- 700 1_
- $a Bochenek, Tomasz $u Department of Nutrition and Drug Research, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland
- 700 1_
- $a Allocati, Eleonora $u Istituto Di Ricerche Farmacologiche 'Mario Negri' IRCCS, Milan, Italy
- 700 1_
- $a Kurdi, Amanj $u Division of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK $u Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa $u Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil, Iraq
- 700 1_
- $a Ogunleye, Olayinka O $u Department of Pharmacology, Therapeutics and Toxicology, Lagos State University College of Medicine, Ikeja, Lagos, Nigeria $u Department of Medicine, Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria
- 700 1_
- $a Meyer, Johanna C $u Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa
- 700 1_
- $a Hoxha, Iris $u Department of Pharmacy, Faculty of Medicine, University of Medicine, Tirana, Albania
- 700 1_
- $a Malaj, Admir $u University of Medicine, Tirana, Albania
- 700 1_
- $a Hierländer, Christian $u Department of Pharmaceutical Affairs, Federation of Social Insurances, Vienna, Austria
- 700 1_
- $a Sauermann, Robert $u Department of Pharmaceutical Affairs, Federation of Social Insurances, Vienna, Austria
- 700 1_
- $a Hamelinck, Wouter $u Statistics Department, Bruxelles, Belgium
- 700 1_
- $a Petrova, Guenka $u Faculty of Pharmacy, Department of Social Pharmacy and Pharmacoeconomics, Medical University of Sofia, Sofia, Bulgaria
- 700 1_
- $a Laius, Ott $u State Agency of Medicines, Tartu, Estonia
- 700 1_
- $a Langner, Irene $u Wissenschaftliches Institut Der AOK (WIdO), Berlin, Germany
- 700 1_
- $a Yfantopoulos, John $u School of National and Kapodistrian University of Athens Athens Greece
- 700 1_
- $a Joppi, Roberta $u Pharmaceutical Drug Department, Azienda Sanitaria Locale of Verona, Verona, Italy
- 700 1_
- $a Jakupi, Arianit $u Faculty of Pharmacy, UBT - Higher Education Institution, Prishtina, Kosovo
- 700 1_
- $a Greiciute-Kuprijanov, Ieva $u Department of Pharmacy, Ministry of Health of the Republic of Lithuania, Vilnius, Lithuania
- 700 1_
- $a Vella Bonanno, Patricia $u Division of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK
- 700 1_
- $a Piepenbrink, Jf Hans $u National Health Care Institute (ZIN), XH, Diemen, Netherlands
- 700 1_
- $a de Valk, Vincent $u National Health Care Institute (ZIN), XH, Diemen, Netherlands
- 700 1_
- $a Wladysiuk, Magdalene $u HTA Consulting, Cracow, Poland
- 700 1_
- $a Marković-Peković, Vanda $u Faculty of Medicine, Department of Social Pharmacy, University of Banja Luka, Banja Luka, Republic of Srpska, Bosnia and Herzegovina
- 700 1_
- $a Mardare, Ileana $u Faculty of Medicine, Public Health and Management Department, "Carol Davila" University of Medicine and Pharmacy Bucharest, Bucharest, Romania
- 700 1_
- $a Fürst, Jurij $u Health Insurance Institute, Ljubljana, Slovenia
- 700 1_
- $a Tomek, Dominik $u Faculty of Medicine, Slovak Medical University in Bratislava, Bratislava, Slovakia
- 700 1_
- $a Obach Cortadellas, Mercè $u Drug Department, Catalan Health Service, Catalan Health Service, Barcelona, Spain
- 700 1_
- $a Zara, Corinne $u Drug Department, Catalan Health Service, Catalan Health Service, Barcelona, Spain
- 700 1_
- $a Pontes, Caridad $u Drug Department, Catalan Health Service, Catalan Health Service, Barcelona, Spain $u Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma De Barcelona, Barcelona, Spain
- 700 1_
- $a McTaggart, Stuart $u Public Health Scotland, Edinburgh, UK
- 700 1_
- $a Laba, Tracey-Lea $u Centre for Health Economics Research and Evaluation, University of Technology Sydney, Broadway, Sydney, NSW
- 700 1_
- $a Melien, Øyvind $u Reviews and Health Technology Assessments, Norwegian Institute of Public Health, Oslo, Norway
- 700 1_
- $a Wong-Rieger, Durhane $u Health Data Science, Institute of Population Health, Liverpool, Canadian Organization for Rare Disorders, Toronto, Ontario, Canada
- 700 1_
- $a Bae, SeungJin $u College of Pharmacy, Ewha Woman's University, Seoul, South Korea
- 700 1_
- $a Hill, Ruaraidh $u Health Data Science, Institute of Population Health Liverpool Reviews and Implementation Group, Whelan Building, University of Liverpool, Liverpool, UK
- 773 0_
- $w MED00174435 $t Expert review of pharmacoeconomics & outcomes research $x 1744-8379 $g Roč. 21, č. 4 (2021), s. 527-540
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33535841 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026134029 $b ABA008
- 999 __
- $a ok $b bmc $g 1714318 $s 1145718
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 21 $c 4 $d 527-540 $e 20210311 $i 1744-8379 $m Expert review of pharmacoeconomics & outcomes research $n Expert rev. pharmacoecon. outcomes res. $x MED00174435
- LZP __
- $a Pubmed-20211013
